Atypical Hemolytic Syndrome __link__ [ Pro — 2026 ]

Induction (weekly x 4) → maintenance (every 2 weeks). For children, weight-based.

Background. Atypical hemolytic uremic syndrome (aHUS) is a rare and heterogeneous disorder. The first line treatment of aHUS is pl... PubMed Central (PMC) (.gov) Atypical Hemolytic Uremic Syndrome: Differential Diagnosis ... - PMC INTRODUCTION * Hemolytic uremic syndrome (HUS) is a rare and severe thrombotic microangiopathy (TMA) characterized by the triad of... PubMed Central (PMC) (.gov) Overcoming technical challenges when treating atypical hemolytic ... Introduction. Hemolytic uremic syndrome (HUS) is a hematological disease characterized mainly by the triad of microangiopathic hem... PubMed Central (PMC) (.gov) HUS and atypical HUS - PMC Among the 30% to 50% of patients with HUS who have no detectable complement defect, some have either impaired diacylglycerol kinas... PubMed Central (PMC) (.gov) Atypical Hemolytic Uremic Syndrome: Causes, Symptoms, and Treatment Oct 3, 2024 — atypical hemolytic syndrome

Managing aHUS requires a multidisciplinary medical team, including nephrologists, hematologists, and genetic counselors. Because the disease is chronic, long-term monitoring is essential to prevent relapses, which can be triggered by infections, pregnancy, or surgery. Induction (weekly x 4) → maintenance (every 2 weeks)

Atypical hemolytic uremic syndrome (aHUS) is a rare and complex blood disorder characterized by the formation of blood clots in small blood vessels throughout the body. It is a type of thrombotic microangiopathy (TMA) that can cause multi-organ dysfunction, including kidney failure. aHUS is distinct from typical hemolytic uremic syndrome (HUS), which is often caused by Shiga toxin-producing E. coli (STEC). Atypical hemolytic uremic syndrome (aHUS) is a rare

Because aHUS is so rare, it is often misdiagnosed. If you or a loved one has unexplained kidney failure paired with anemia, ask your specialist about aHUS. Early diagnosis saves kidneys, and it saves lives.

Mandatory Neisseria meningitidis vaccination (serogroups A, C, W, Y, B) at least 2 weeks prior, plus prophylactic antibiotics (penicillin or ciprofloxacin) due to encapsulated organism risk.

The root of aHUS lies in the "alternative pathway" of the complement system. In a healthy body, this system identifies and destroys foreign invaders like bacteria. In patients with aHUS, genetic mutations prevent the body from "turning off" this immune response. As a result, the complement system attacks the body’s own healthy cells, specifically the endothelium (the lining of the blood vessels).